METHOD FOR PREDICTION OF EXCESSIVE ARTERIAL STIFFNESS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE 12 MONTHS AFTER SUFFERING COVID-19 Russian patent published in 2025 - IPC G01N33/68 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pulmonology and therapy, and can be used to predict excessive arterial stiffness in patients with chronic obstructive pulmonary disease (COPD) 12 months after suffering COVID-19. Performing blood sampling and determining initial concentrations of endothelial dysfunction and systemic inflammation in blood serum: interleukin 10 (IL-10), pg/ml, monocytic chemotactic protein (MCP-1), pg/ml, total homocysteine (Hcy), mcmol/l. P value is calculated by solving the logit regression equation: P=1/1+e^{-(10.5-0.65*Hcy-0.09*MCP-1+0.14*IL-10)}, where: P – probability of detecting cardio-ankle vascular index on the right or on the left (R/L-CAVI) is higher than 8.5 units in a patient with COPD 12 months after suffering COVID-19. If P is less than or equal to 0.5, the value of the R/L-CAVI index is higher than 8.5 units, which corresponds to excessive arterial stiffness. If P is more than 0.5, R/L-CAVI is predicted to be 8.5 units or less, which corresponds to normal arterial stiffness.

EFFECT: method enables reliable prediction of excessive or normal arterial stiffness by R/L-CAVI index in patients with COPD 12 months after suffering COVID-19 by evaluating the probability of detecting the CAVI index on the right or on left above 8.5 units in patients with COPD, suffered COVID-19, based on serum concentration of the following indicators of endothelial dysfunction and systemic inflammation: interleukin 10, monocytic chemotactic protein and total homocysteine.

1 cl, 2 ex